21 CFR § 522.1850Chapter I

§ 522.1850 Polysulfated glycosaminoglycan.

Primary source

Verbatim text below is from the Electronic Code of Federal Regulations (eCFR), a public-domain U.S. government work. Always verify the current version with the eCFR before relying on it for any legal matter.

Full Text

Specifications.(a) (1) Each 1-milliliter (mL) ampule of solution contains 250 milligrams (mg) polysulfated glycosaminoglycan.

(2) Each mL of solution packaged in 5-mL ampules or 20-, 30-, or 50-mL vials contains 100 mg polysulfated glycosaminoglycan.

Sponsor.(b) See No. 010797 in § 510.600(c) of this chapter.

Special considerations.(c) Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Conditions of useHorsesIndications for use.(d) —(1) —(i) For the treatment of noninfectious degenerative and/or traumatic joint dysfunction and associated lameness of the carpal and hock joints in horses.

AmountIntra-articular use (carpal)(ii) —(A) : 250 mg once a week for 5 weeks.

Intramuscular use (carpal and hock)(B) : 500 mg every 4 days for 28 days.

Limitations.(iii) Do not use in horses intended for human consumption.

DogsIndications for use.(2) —(i) For control of signs associated with noninfectious degenerative and/or traumatic arthritis of canine synovial joints.

Amount.(ii) 2 mg per pound of body weight by intramuscular injection twice weekly for up to 4 weeks (maximum of 8 injections).

[72 FR 56896, Oct. 5, 2007, as amended at 74 FR 67816, Dec. 21, 2009]

eCFR data current as of: June 10, 2026

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.